Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ELVN NASDAQ:INVA NASDAQ:PGEN NASDAQ:RCKT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELVNEnliven Therapeutics$20.68-0.7%$19.77$13.30▼$30.03$1.23B0.85578,428 shs510,219 shsINVAInnoviva$16.94-2.4%$19.32$16.67▼$22.00$1.09B0.4760,541 shs596,402 shsPGENPrecigen$3.21+2.9%$3.47$0.65▼$5.22$929.68M1.615.95 million shs5.75 million shsRCKTRocket Pharmaceuticals$3.47+1.5%$3.23$2.19▼$18.89$369.03M0.62.66 million shs2.22 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELVNEnliven Therapeutics-0.67%+1.87%+3.61%-4.48%-25.90%INVAInnoviva-2.36%-2.76%-12.55%-15.13%-14.44%PGENPrecigen+2.88%+2.23%-15.30%+73.51%+257.22%RCKTRocket Pharmaceuticals+1.46%+9.12%+9.81%+23.49%-79.72%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELVNEnliven Therapeutics$20.68-0.7%$19.77$13.30▼$30.03$1.23B0.85578,428 shs510,219 shsINVAInnoviva$16.94-2.4%$19.32$16.67▼$22.00$1.09B0.4760,541 shs596,402 shsPGENPrecigen$3.21+2.9%$3.47$0.65▼$5.22$929.68M1.615.95 million shs5.75 million shsRCKTRocket Pharmaceuticals$3.47+1.5%$3.23$2.19▼$18.89$369.03M0.62.66 million shs2.22 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELVNEnliven Therapeutics-0.67%+1.87%+3.61%-4.48%-25.90%INVAInnoviva-2.36%-2.76%-12.55%-15.13%-14.44%PGENPrecigen+2.88%+2.23%-15.30%+73.51%+257.22%RCKTRocket Pharmaceuticals+1.46%+9.12%+9.81%+23.49%-79.72%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceELVNEnliven Therapeutics 2.67Moderate Buy$41.2099.23% UpsideINVAInnoviva 2.71Moderate Buy$37.60121.96% UpsidePGENPrecigen 2.50Moderate Buy$8.25157.01% UpsideRCKTRocket Pharmaceuticals 2.33Hold$16.67380.31% UpsideCurrent Analyst Ratings BreakdownLatest PGEN, RCKT, INVA, and ELVN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025ELVNEnliven TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025INVAInnovivaZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy10/8/2025INVAInnovivaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)10/8/2025PGENPrecigenWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025RCKTRocket PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/3/2025RCKTRocket PharmaceuticalsLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Perform$9.00 ➝ $7.009/30/2025INVAInnovivaThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageSell$17.009/30/2025INVAInnovivaThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageSell$17.009/27/2025ELVNEnliven TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025INVAInnovivaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)9/27/2025PGENPrecigenWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 10/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookELVNEnliven TherapeuticsN/AN/AN/AN/A$6.34 per shareN/AINVAInnoviva$358.71M2.98$3.35 per share5.06$11.03 per share1.54PGENPrecigen$3.92M244.00N/AN/A$0.13 per share24.69RCKTRocket PharmaceuticalsN/AN/AN/AN/A$5.08 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateELVNEnliven Therapeutics-$89.02M-$2.00N/AN/AN/AN/A-29.15%-27.88%11/12/2025 (Estimated)INVAInnoviva$23.39M$0.3154.6510.93N/A10.44%18.67%9.92%11/5/2025 (Estimated)PGENPrecigen-$126.24M-$0.42N/AN/AN/A-2,868.66%-842.83%-78.98%11/13/2025 (Estimated)RCKTRocket Pharmaceuticals-$258.75M-$2.51N/AN/AN/AN/A-65.11%-55.99%11/6/2025 (Estimated)Latest PGEN, RCKT, INVA, and ELVN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025RCKTRocket Pharmaceuticals-$0.48N/AN/AN/A$0.33 millionN/A11/5/2025Q3 2025INVAInnoviva$0.46N/AN/AN/A$91.31 millionN/A8/13/2025Q2 2025ELVNEnliven Therapeutics-$0.53-$0.49+$0.04-$0.49N/AN/A8/12/2025Q2 2025PGENPrecigen-$0.14-$0.11+$0.03-$0.09$0.67 million$0.86 million8/7/2025Q2 2025RCKTRocket Pharmaceuticals-$0.57-$0.59-$0.02-$0.62$4.36 millionN/A8/6/2025Q2 2025INVAInnoviva$0.57$0.77+$0.20$0.77$87.10 million$100.28 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthELVNEnliven TherapeuticsN/AN/AN/AN/AN/AINVAInnovivaN/AN/AN/AN/AN/APGENPrecigenN/AN/AN/AN/AN/ARCKTRocket PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioELVNEnliven TherapeuticsN/A32.5832.58INVAInnoviva0.362.642.44PGENPrecigenN/A2.712.71RCKTRocket Pharmaceuticals0.056.396.39Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipELVNEnliven Therapeutics95.08%INVAInnoviva99.12%PGENPrecigen33.51%RCKTRocket Pharmaceuticals98.39%Insider OwnershipCompanyInsider OwnershipELVNEnliven Therapeutics25.90%INVAInnoviva2.25%PGENPrecigen47.10%RCKTRocket Pharmaceuticals24.76%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableELVNEnliven Therapeutics5059.24 million43.89 millionOptionableINVAInnoviva10063.02 million61.60 millionOptionablePGENPrecigen190297.97 million157.63 millionOptionableRCKTRocket Pharmaceuticals240107.90 million81.19 millionOptionablePGEN, RCKT, INVA, and ELVN HeadlinesRecent News About These CompaniesRocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 10, 2025 | finance.yahoo.comRocket Pharmaceuticals (NASDAQ:RCKT) Receives "Sell (E+)" Rating from Weiss RatingsOctober 10, 2025 | marketbeat.comRocket Pharmaceuticals (NASDAQ:RCKT) Shares Pass Below 50-Day Moving Average - What's Next?October 8, 2025 | marketbeat.comLeerink Partners Issues Pessimistic Forecast for Rocket Pharmaceuticals (NASDAQ:RCKT) Stock PriceOctober 5, 2025 | americanbankingnews.comLeerink Partners Maintains Rocket Pharmaceuticals (RCKT) Market Perform RecommendationOctober 4, 2025 | msn.comRocket Pharmaceuticals (NASDAQ:RCKT) Price Target Cut to $7.00 by Analysts at Leerink PartnersOctober 3, 2025 | marketbeat.comRocket Pharmaceuticals withdraws US application of gene therapy for rare blood disorderOctober 3, 2025 | reuters.comBrokerages Set Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Target Price at $16.73October 3, 2025 | americanbankingnews.comRocket Pharmaceuticals (NASDAQ:RCKT) Stock Price Passes Below Fifty Day Moving Average - What's Next?September 30, 2025 | marketbeat.comRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Given Average Rating of "Hold" by AnalystsSeptember 30, 2025 | marketbeat.comSovran Advisors LLC Sells 127,063 Shares of Rocket Pharmaceuticals, Inc. $RCKTSeptember 20, 2025 | marketbeat.comKuehn Law Encourages Investors of Rocket Pharmaceuticals, Inc. to Contact Law FirmSeptember 19, 2025 | prnewswire.comRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Sees Significant Growth in Short InterestSeptember 18, 2025 | marketbeat.comGoldman Sachs Group Inc. Has $6.64 Million Stock Position in Rocket Pharmaceuticals, Inc. $RCKTSeptember 16, 2025 | marketbeat.comRocket Pharmaceuticals, Inc. (RCKT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 9, 2025 | seekingalpha.comElisabeth Bjork Buys 10,000 Shares of Rocket Pharmaceuticals (NASDAQ:RCKT) StockAugust 28, 2025 | insidertrades.comRocket Pharmaceuticals CFO Aaron Ondrey resigns to pursue other opportunitiesAugust 25, 2025 | msn.comEMA says Rocket Pharmaceuticals withdraws MA application for FanskyaAugust 22, 2025 | msn.comRocket Pharmaceuticals: Good News As Clinical Hold Lifted - But Challenges RemainAugust 22, 2025 | seekingalpha.comRocket Pharmaceuticals (RCKT) Receives a Sell from Goldman SachsAugust 22, 2025 | theglobeandmail.comRCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease StudyAugust 21, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePGEN, RCKT, INVA, and ELVN Company DescriptionsEnliven Therapeutics NASDAQ:ELVN$20.68 -0.14 (-0.67%) Closing price 10/13/2025 04:00 PM EasternExtended Trading$20.69 +0.01 (+0.05%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.Innoviva NASDAQ:INVA$16.94 -0.41 (-2.36%) Closing price 10/13/2025 04:00 PM EasternExtended Trading$16.93 -0.01 (-0.03%) As of 10/13/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.Precigen NASDAQ:PGEN$3.21 +0.09 (+2.88%) Closing price 10/13/2025 04:00 PM EasternExtended Trading$3.22 +0.02 (+0.47%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.Rocket Pharmaceuticals NASDAQ:RCKT$3.47 +0.05 (+1.46%) Closing price 10/13/2025 04:00 PM EasternExtended Trading$3.52 +0.05 (+1.56%) As of 04:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise D-Wave: Reevaluating the Short Seller’s Case After the Downgrade 2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk Applied Digital’s Shorts Got Squeezed—Now What? Levi Strauss Stock Set to Reach New Highs in 2026 Alphabet: The AI Powerhouse Driving Markets Into 2026 Is the Reddit-ChatGPT Love Affair Over? Broadcom Gets Second $420 Target as CPO Win Boosts Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
